Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2651 - 2675 of 3650 in total
Investigational
Experimental
Matched Iupac: … 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,7,8,9-tetrahydro-3H-purin-6-one …
Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has...
Investigational
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
Investigational
Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
Investigational
Matched Synonyms: … INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED …
RO7200220 is a recombinant fully humanized anti-IL 6 monoclonal antibody.
Investigational
An essential amino acid that is required for the production of histamine.
Investigational
Nutraceutical
Matched Salts cas: … 13870-80-9
Matched Mixtures name: … Aminosyn II 7% With 10% Dextrose ... Aminosyn II 7% M In 10% Dextrose(dual Chamber) ... Aminosyn 7% …
Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 10% Dextrose ... Aminosyn II 7% M In 10% Dextrose(dual Chamber) ... Aminosyn 7% …
Incadronate, or YM-175, is a nitrogen containing bisphosphonate. Along with being investigated to treat hypercalcemia of malignancy, it has also been investigated in the treatment of myeloma, leukemia, and other cancers.[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.
Experimental
Experimental
Matched Name: … N-[(13-CYCLOHEXYL-6,7-DIHYDROINDOLO[1,2-D][1,4]BENZOXAZEPIN-10-YL)CARBONYL]-2-METHYL-L-ALANINE …
Matched Iupac: … 2-({18-cyclohexyl-8-oxa-11-azatetracyclo[9.7.0.0^{2,7}.0^{12,17}]octadeca-1(18),2(7),3,5,12,14,16-heptaen …
Investigational
Matched Iupac: … 2-yl]-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7- …
Investigational
Investigational
Experimental
Experimental
Matched Iupac: … (3S,4R,5S,6S)-5-hydroxy-6-[(4-hydroxy-3-{5-[(4-hydroxy-7-{[(2S,3S,4R,5S)-3-hydroxy-5-methoxy-6,6-dimethyl ... oxy}-8-methyl-2-oxo-2H-chromen-3-yl)carbamoyl]-4-methyl-1H-pyrrole-3-amido}-8-methyl-2-oxo-2H-chromen-7- …
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Investigational
Experimental
Experimental
Matched Name: … 18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9- …
Experimental
Matched Name: … ,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9- …
Displaying drugs 2651 - 2675 of 3650 in total